Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway Pittsburgh, PA, August 27, 2024 – Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York City at the Lotte New York Palace Hotel on September 9 through 11, 2024. Admission to H.C. Wainwright’s conference is for qualified investors, and Lipella will be giving a virtual...
![Lipella Pharmaceuticals to Participate at H.C. Wainwright’s 26th Annual Global Investment Conference in New York](https://prismmediawire.com/wp-content/uploads/2024/08/Newsroom-May-2024-3.png)